WaveMan
WaveMan · Company
SHPH · Shuttle Pharmaceuticals Holdings, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

SHPH Shuttle Pharmaceuticals (SHPH) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001757499
Quote by TradingView
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

What the filings say about SHPH

Insiders, 180 days
-$323.1K net sold
1 buyer · 1 seller · 0% of sales under a 10b5-1 plan

Shuttle Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Shuttle Pharmaceuticals Holdings, Inc. insiders sold a net $323.1K of stock across 23 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
HRT FINANCIAL LP
SELL
2026-07-15 SECtraded 2026-07-14
82,116
$367.9K
+42.1%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (6 buys, 4 sales), the last on Jul 13, 2026.
  • +26.5% median (+35.8% mean) 90-day return after 6 previous buys.
  • No other insider sold within 30 days.
Insider activity: Insider HRT FINANCIAL LP sold about $367.9K of SHPH on Jul 14, 2026, the largest insider sale at the company on our record.
HRT FINANCIAL LP
SELL
2026-07-15 SECtraded 2026-07-13
1,033
$4.8K
+42.1%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (6 buys, 3 sales), the last on Jul 10, 2026.
  • +26.5% median (+35.8% mean) 90-day return after 6 previous buys.
  • The trade is 1.7% of the 60,238 shares held after it.
  • No other insider sold within 30 days.
Insider activity: Insider HRT FINANCIAL LP sold about $4.8K of SHPH on Jul 13, 2026.
HRT FINANCIAL LP
BUY
2026-07-13 SECtraded 2026-07-10
731
$2.3K
+21.3%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (5 buys, 3 sales), the last on Jul 9, 2026.
  • +26.5% median (+24.9% mean) 90-day return after 5 previous buys.
  • The trade is 1.2% of the 61,271 shares held after it.
  • No other insider bought within 30 days.
Insider activity: Insider HRT FINANCIAL LP bought about $2.3K of SHPH on Jul 10, 2026.
HRT FINANCIAL LP
BUY
2026-07-13 SECtraded 2026-07-09
8,266
$27.9K
+21.3%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (4 buys, 3 sales), the last on Jul 8, 2026.
  • +20.9% median (+20.3% mean) 90-day return after 4 previous buys.
  • The trade is 13.7% of the 60,540 shares held after it.
  • No other insider bought within 30 days.
Insider activity: Insider HRT FINANCIAL LP bought about $27.9K of SHPH on Jul 9, 2026.
HRT FINANCIAL LP
SELL
2026-07-09 SECtraded 2026-07-08
18,531
$65.2K
+72.8%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (4 buys, 2 sales), the last on Jul 7, 2026.
  • +20.9% median (+20.3% mean) 90-day return after 4 previous buys.
  • The trade is 35.4% of the 52,274 shares held after it.
  • No other insider sold within 30 days.
Insider activity: Insider HRT FINANCIAL LP sold about $65.2K of SHPH on Jul 8, 2026, the largest insider sale at the company on our record.
23 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 18 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$323.1K over 180 days
-$323.1K of it by a 10%+ holder
below 52% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
0.7% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 77% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 5 in the prior 90
Why it matters
The absence is the signal: 5 sales in one 90-day window and none in the next is a change of behaviour, not a filing.
Oct 28Insider buying stopped: no purchases in 90 days after 6 in the prior 90
Why it matters
The absence is the signal: 6 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch SHPH

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-83.7%12M
-91%-59%-28%+4%2025-102025-122026-022026-042026-062026-082026-10 2026-07-14 · HRT FINANCIAL LP sold $367.9K2026-06-29 · HRT FINANCIAL LP bought $88.9K2026-07-08 · HRT FINANCIAL LP sold $65.2K2026-07-07 · HRT FINANCIAL LP sold $35.2K2026-07-06 · HRT FINANCIAL LP sold $31.7K2026-07-09 · HRT FINANCIAL LP bought $27.9K2026-07-02 · HRT FINANCIAL LP bought $27.8K2026-06-30 · HRT FINANCIAL LP bought $21.8K2026-07-01 · HRT FINANCIAL LP bought $13.1K2026-07-13 · HRT FINANCIAL LP sold $4.8K2026-07-10 · HRT FINANCIAL LP bought $2.3K
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns SHPH: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in SHPH

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

SHPH planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $323.1K sold by insiders over 180 days. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

SHPH financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
0.00x
long-term debt only, 2021-12-31 (54 months older than the period end); equity 2026-06-30
Cash flow to debt
-72.34x
TTM operating cash flow over long-term debt only, 2021-12-31 (54 months older than the period end)
Return on equity
-90.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-72.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-97.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$24.0M
market value at close 2026-10-26 on 2026-09-21 shares, plus long-term debt only, 2021-12-31 (54 months older than the period end), minus cash 2026-06-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$11.9M-$7.7M-$5.9M-$2.3M
Net income-$11.7M-$9.1M-$6.6M-$5.0M
EPS (diluted)-7.16-82.60-3.53-5.04
Operating cash flow-$9.5M-$7.3M-$5.6M-$2.7M
Cash$334.0K$1.9M$2.6M$8.4M
SEC XBRL, fiscal years, as known on 2026-10-28

SHPH Stock Sonar score 4/7 axes

Find similar shapesCompare

SHPH ranks highest on risk and compliance (84th percentile) and insider conviction (51st), and lowest on profitability (32nd), among Pharma & Biotech peers.

Profitability
32
Inputs
  • Return on equity-90.1% · 36 pct, sector of 545
  • Return on assets-72.5% · 33 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-97.0% · 26 pct, sector of 576
Financial health
45
Inputs
  • Debt to equity0.00x · 80 pct, sector of 352
  • Cash flow to debt-72.34x · 9 pct, sector of 371
Insider conviction
51
Inputs
  • Net Form 4 buying (codes P and S), 180d-$323K · 46 pct, sector of 429
  • Insider buyers, 180d1 · 56 pct, sector of 438
Risk and compliance
84
Inputs
  • Short interest, % of float+0.7% · 84 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Growth, Institutional and government, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

SHPH filings, in plain words

Are Shuttle Pharmaceuticals insiders buying or selling SHPH?

In the 180 days to 2026-10-28, Shuttle Pharmaceuticals insiders were net sellers, a net $323.1K: $181.8K of purchases and $504.8K of sales reported on Form 4, by 1 buyer and 1 seller.

Read the full summary

In the 180 days to 2026-10-28, Shuttle Pharmaceuticals insiders were net sellers of SHPH, a net $323.1K across purchases and sales reported on Form 4 by 1 buyer and 1 seller. Most of that figure, $323.1K, came from a holder of 10% or more rather than an officer or director. None of the 5 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies